Andres Poveda, MD Initia Oncology Hospital Quironsalud Valencia, Spain 5 Live #ASCO20
4:57
Key Insights on Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Key Insights on Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
Gynecologic Malignancies Similar Videos
-
Ritu Salani, MD, MBA; David Geffen School of Medicine at UCLA; 5Live; #ASCO2021
4:35
-
Elisabeth Driver, MD; Stanford Cancer Institute; 5Live #SGO22
3:36
Key Insights from the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting #SGO22
-
Thomas J. Herzog, MD; University of Cincinnati Cancer Center; 5Live; #ASCO21
8:12